Concert Pharmaceuticals Releases Information on Upcoming CTP-543 Phase 3 Trials
Leading off of the Phase 2 CTP-543 trials, Chief Development Officer of Concert Pharmaceuticals, Dr. James V. Cassella states: “The planned initiation of the Phase 3 program, combined with the positive results of the Phase 2 dose ranging trial, show the continued momentum for our development of CTP-543 for patients with alopecia areata,” The
Phase 2 of CTP-543 Trial Brings Positive News
Positive results have been reported following the completion of the CTP-543 Phase 2 trial. More than 75% of patients receiving two daily 12mg dosages of CTP-543 confirmed that their alopecia had "very much improved" or "much improved" after 24 weeks. Plans for phase 3 are on the way and scheduled to start in 2020.
Clinical Trials Now Recruiting in Ontario & Quebec
Clinical trials are being conducted by Concert Pharmaceuticals Inc., to investigate a new treatment called CTP‑543 in adults, age 18 to 65 years, with at least 50% hair loss. This research study will look at 2 different dosing regimens (schedules) of CTP-543 when given to research participants with alopecia areata for a total of
The Promising Treatment CTP-543: Once or Twice Daily?
Concert Pharmaceutical's research team has recently initiated open label trials to determine the optimal dosage rate of the compound CTP-543 for those with moderate-to-severe alopecia areata. This research will inform future trials and is important in understanding the effects of a single daily dosage compared to two. The treatment process will last 24 weeks is expected to be completed later this year. Follow this link for
Concert Pharmaceuticals Reports on New Treatment for Alopecia Areata
Concert Pharmaceuticals is a leading company for the development of treatments similar to topical tofacitinib and topical ruxolitinib, both of which are topical JAK inhibitors. Recent trials and treatment analysis have shown positive results for regrowth in patients with Alopecia Areata. For more information, please follow the links below: Concert Pharmaceuticals: https://www.concertpharma.com/ Scientific Presentation: https://www.concertpharma.com/wp-content/uploads/2018/11/CTP-543-Phase-2a-Topline-Results-FINAL-12NOV18.pdf
Dr. Donovan Article: Topical JAK inhibitors for Treating AA in Children/Adolescents
For the latest research article from Dr. J. Donovan, please click on this link: Canaaf June 2017 Thank you Dr. Donovan for this research information.
Watch Dr. Donovan’s update from 2020 and learn about recent advancements in alopecia research.